Pricing updated 2019-04-24. Prices are subject to change without notice.
SMYD2 is a lysine N-methyltransferase that methylates both histones and non-histone proteins, including p53 and retinoblastoma-associated protein.1,2 LLY-507 is a cell-active, small molecule inhibitor of SMYD2 (IC50 = 15 nM).3 It has been shown to inhibit p53 lysine370 monomethylation in KYSE-150 esophageal squamous cell carcinoma cells stably expressing SMYD2 with an IC50 value of 0.6 µM.3 LLY-507 is >100-fold selective for SMYD2 over a panel of 27 protein methyltransferases and non-methyltransferase targets.3 See the Structural Genomics Consortium (SGC) website for more information.
Warning - this product is not for human or veterinary use.
View the Cayman Structure Database for chemical structure definitions for many Cayman products
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data pack, and GC-MS data.
Brown, M.A., Sims, R.J., III, Gottlieb, P.D., et al. Identification and characterization of Smyd2: A split SET/MYND domain-
Lee, K., Lee, J.H., Boovanahalli, S.K., et al. (Aryloxyacetylamino)benzoic acid analogues: A new class of hypoxia-